Interferon-alpha, you can fully epidemic type I diabetes

A low dose oral interferon alpha shows promise for preserving beta cell function in patients newly diagnosed with type 1 diabetes or juvenile diabetes, by researchers at the University of Texas Medical School at Houston.

The results of Phase II are today in Diabetes Care, a journal of the American Diabetes Association.

"It shows a strong tendency to preserve insulin production in beta cells function is significantly better than placebo," said Staley Brod, MD, principal investigator of the study, the National Institute of Diabetes and gastrointestinal disorders and kidney diseases (NIDDK). "This may be the" Honeymoon phase "of the disease, so that the body produce more insulin by beta cells, which is correlated with a reduction in the rate of complications."

Like many 3 million Americans may have Type I diabetes, early juvenile diabetes, the Juvenile Diabetes Research Foundation International. Each year, 15,000 children in self-diagnosis of the disease in the pancreas stops producing insulin to glucose in the blood into cells for energy. The result is too much glucose in the blood, which causes kidney failure, blindness, nerve damage, amputation, myocardial infarction and stroke.

A honeymoon phase sometimes occurs only after the diagnosis, because the body tries to rebound. Many patients live a time when their need for insulin is minimal, blood sugar control and improve beta cell partial recovery. If the pancreas is still able to function, the ups and downs, it has created insulin may be reduced.

The Phase II study, 128 patients in the internal review of the NIDDK Office, The University of Texas Southwestern Medical Center at Dallas and Children Hospital and Clinics in Minneapolis / St. Paul, Minn. research was to University of Texas Clinical Research Center at Memorial Hermann-Texas Medical Center, part of the Center for Clinical and Translational Science at the University of Texas Health Science Center in Houston.

Research topics at the age of 3 to 25 with the diagnosis of type 1 diabetes within six weeks after enrollment, were randomized and received 5000 units of interferon alpha, 30,000 units of interferon alpha or placebo once daily for a period of one year. Patients lost 5000 units, only 29% of beta cell function compared to 48% for patients, 30,000 units and 56 percent for patients in the placebo group.

Austin established Wallquist Jarod, 11, was 5 years old, when he was diagnosed with type I diabetes and his mother, Amy learned about Brod study. Jarod 5000, units of interferon alpha, but neither they nor the scientists knew it was time, because the double blind study.

"My husband and I are both science-minded, so that we can understand the importance of research, even if we do not know if it would, Jarod," said Wallquist, whose family of a journey regular in Houston for the study. "Jarod is really good. It covers an insulin pump, but he never had, for emergencies. To date, according to his doctor, his insulin levels used, is much lower than other children of his age and weight. He plays baseball and is in the Baden-team, and he has a life quite normal. "

The research builds on previous studies on Brod oral interferon alpha and animals in a phase I study of safety. According to the study of security, NIDDK researchers invited to Brod of research of Phase II.

Brod-theory is that autoimmune diseases, which occur when the body's own immune system, are in fact an interferon alpha-immunodeficiency syndrome. Interferons are a group of proteins, cells, in response to an attack by a virus.